Alli: Clinically Proven Weight Loss Aid for Adults
Alli
| Product dosage: 60mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.37 | $41.00 (0%) | 🛒 Add to cart |
| 60 | $1.10 | $82.00 $66.00 (20%) | 🛒 Add to cart |
| 90 | $1.01 | $123.00 $91.00 (26%) | 🛒 Add to cart |
| 120 | $0.97 | $164.00 $117.00 (29%) | 🛒 Add to cart |
| 180 | $0.93 | $246.00 $168.00 (32%) | 🛒 Add to cart |
| 270 | $0.90 | $369.00 $243.00 (34%) | 🛒 Add to cart |
| 360 | $0.88
Best per pill | $492.00 $317.00 (36%) | 🛒 Add to cart |
Synonyms | |||
Alli (orlistat 60 mg) is the only FDA-approved over-the-counter weight loss aid that works in the gut to prevent the absorption of about 25% of dietary fat. It is designed for use by overweight adults in conjunction with a reduced-calorie, low-fat diet and regular physical activity. By blocking fat absorption, Alli supports sustainable weight management when integrated into a structured lifestyle plan. This non-systemic agent offers a pharmacologically grounded approach to complement behavioral modifications in obesity treatment.
Features
- Contains orlistat 60 mg per capsule
- Non-systemic mode of action—works locally in the gastrointestinal tract
- Prevents absorption of approximately 25% of dietary fat
- Gluten-free formulation
- Available without prescription for adults with a BMI ≥25
- Packaged with tailored dietary guidance materials
Benefits
- Supports clinically meaningful weight loss when combined with diet and exercise
- Encourages adherence to a lower-fat dietary regimen through its mechanism
- Provides a non-stimulant alternative to centrally-acting appetite suppressants
- Helps establish long-term healthier eating patterns
- Contributes to improvements in weight-related metabolic parameters
- Empowers users with evidence-based tools for weight management
Common use
Alli is indicated for weight management in overweight adults, aged 18 years and older, used in conjunction with a reduced-calorie and low-fat diet. It is intended for individuals with an initial body mass index (BMI) of 25 or greater. Typical users include those seeking a pharmacological adjunct to lifestyle modification who have had difficulty losing weight through diet and exercise alone. It is often incorporated into a broader weight management strategy that may include behavioral therapy, nutritional counseling, and increased physical activity.
Dosage and direction
The recommended dosage is one 60 mg capsule taken orally three times daily with each main meal containing fat (up to 30% of calories from fat). The capsule should be taken during the meal or up to one hour after eating. If a meal is missed or contains no fat, the dose of Alli should be omitted. Daily fat intake should be distributed evenly over three main meals. Supplementation with a multivitamin containing fat-soluble vitamins (A, D, E, K) is recommended, taken at least 2 hours before or after Alli administration to ensure adequate absorption.
Precautions
- Not intended for use by individuals with eating disorders such as anorexia or bulimia
- Should not be used during pregnancy or breastfeeding
- Use with caution in patients with history of hyperoxaluria or calcium oxalate nephrolithiasis
- Monitor for possible decreases in cyclosporine levels if used concomitantly
- Periodic monitoring of lipid-soluble vitamin levels is advised during prolonged use
- Not recommended for use beyond two years without medical reassessment
Contraindications
- Chronic malabsorption syndrome
- Cholestasis
- Hypersensitivity to orlistat or any component of the formulation
- Organ transplant recipients receiving immunosuppressive therapy
- Concurrent use with acarbose or other lipase inhibitors
- Patients taking warfarin or other anticoagulants (requires close monitoring)
Possible side effects
Gastrointestinal adverse events are common due to the local mechanism of action and are generally dose-dependent and related to dietary fat intake. These may include:
- Oily spotting
- Flatus with discharge
- Fecal urgency
- Fatty/oily stool
- Oily evacuation
- Increased defecation
- Fecal incontinence
These effects are usually transient and diminish with continued use as patients adapt to a lower-fat diet. Less commonly, side effects may include abdominal discomfort/pain, nausea, infectious diarrhea, rectal pain, tooth/gum disorder, headache, upper respiratory infection, and menstrual irregularities.
Drug interactions
- Warfarin: May potentiate anticoagulant effect—monitor INR regularly
- Cyclosporine: Reduced cyclosporine absorption—administer 2 hours before or after Alli
- Levothyroxine: May decrease efficacy—separate administration by at least 4 hours
- Antiepileptic drugs: Possible reduced absorption—monitor drug levels
- Amiodarone: Potential decreased absorption
- Fat-soluble vitamins: Impaired absorption—supplement separately as directed
- Oral contraceptives: Theoretical risk of reduced efficacy—consider backup method
Missed dose
If a dose is missed, it should be skipped and the regular dosing schedule resumed with the next meal. Do not double the dose to make up for a missed capsule. Consistency with meal timing optimizes therapeutic effect while minimizing gastrointestinal adverse events.
Overdose
Cases of overdose have been reported with doses up to 400 mg orlistat daily. The most likely manifestations are gastrointestinal events similar to the known side effects but potentially more severe. There is no specific antidote. Treatment should be symptomatic and supportive, including maintenance of hydration. Medical attention should be sought if severe abdominal pain or persistent diarrhea occurs.
Storage
Store at room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep the bottle tightly closed and protect from moisture and light. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Individual results may vary. Alli should be used as part of a comprehensive weight management program under appropriate conditions. Consult a healthcare professional before starting any new medication or weight loss program, especially if you have underlying medical conditions or are taking other medications. Not all users will experience the same results or side effects.
Reviews
Clinical studies demonstrate that Alli, combined with lifestyle modification, produces significantly greater weight loss than placebo plus lifestyle modification alone. In a 6-month study, 40% of Alli users achieved ≥5% weight loss compared to 22% with placebo. Longer-term data support maintenance of weight loss with continued use. Real-world evidence suggests that gastrointestinal side effects decrease over time as dietary fat intake is moderated. User experiences vary, with successful outcomes correlating strongly with adherence to dietary recommendations and integration with behavioral changes.